EXTON, PA — ProRx Pharma says it has begun commercial distribution of a needle-free oral testosterone therapy, positioning the product as a first-of-its-kind alternative designed to deliver the effects of injectable testosterone without in-person injections.
The company announced the availability of the liquid oral testosterone as demand for hormone replacement therapy grows alongside the expansion of telemedicine, med spas, and clinic-based care models. ProRx said the formulation is intended to help providers scale testosterone replacement therapy, or TRT, without the clinical complexity and logistical burdens tied to injectable protocols.
Injectable testosterone typically requires in-office visits, sterile procedures, and heightened clinical oversight. ProRx said its oral option removes those barriers, allowing providers to prescribe and dispense therapy remotely while reducing procedural risks associated with injections.
“Injectable testosterone has long been part of treatment protocols, but it is not always practical for every care setting,” said Kurt Lunkwitz, ProRx Pharma’s chief operating officer. “ProRx’s oral testosterone provides clinicians with an additional administration option that can better align with both in-person and virtual models of care.”
The company said declining testosterone levels, which commonly occur with age, are often associated with fatigue, reduced muscle mass, weight gain, mood changes, and diminished physical performance. ProRx said its oral TRT is designed to support muscle strength, energy, cognitive and sexual function, and cardiovascular health, while improving patient adherence by eliminating needles and frequent clinic visits.
ProRx highlighted several advantages it says the oral therapy offers telemedicine providers, including a scalable, low-touch delivery model suited to high-volume platforms, reduced clinical overhead and injection-related risks, and more consistent hormone levels compared with the peaks and troughs often associated with weekly injections. The company also said the oral format may improve patient adoption among those who are needle-averse.
Manufacturing takes place at ProRx’s state-licensed, FDA-registered 503B outsourcing facility, where each batch undergoes third-party potency and BioBurden testing. The company said production follows U.S. Pharmacopeia <800> standards and current Good Manufacturing Practices, or cGMP, with an emphasis on regulatory compliance and patient safety.
The oral testosterone is supplied in 1-milliliter daily-use ampules and is intended to be ready for dispensing across a range of care settings, from traditional clinics to fully virtual platforms.
ProRx said the launch reflects broader shifts in how hormone therapies are delivered, as healthcare providers increasingly look for treatment options that align with remote care models and patient preferences while maintaining clinical reliability.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.